Clinical Trial Update: Phase II Study of Pazopanib and Topotecan in Cervical Cancer [Phase 2]

View source ↗

Summary

Phase II trial of pazopanib in combination with topotecan for cervical cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Hycamtin (Topotecan)
• Votrient (Pazopanib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cervical Cancer | Phase 2 | Status: WITHDRAWN